RXRX
What one share of Recursion Pharmaceuticals holds
Biological Products, (No Diagnostic Substances)
Recursion is a clinical-stage TechBio company with a mission to decode biology to radically improve lives. We have advanced a portfolio of differentiated internal programs and strategic partnerships powered by our integrated drug discovery and development platform, the Recursion Operating System (OS).
Recursion Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.11 |
|---|---|
| Profit | −$1.02 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.69 |
| Cash and investments | $1.02 |
| Debt | $0.03 |
| Book value | $1.71 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $0.11 | −$2.87 | $0.18 | −$2.83 | — | −$5.76 |
| 2020 | $0.18 | −$3.99 | $0.27 | −$2.35 | — | −$9.24 |
| 2021 | $0.08 | −$1.49 | $0.32 | −$1.58 | — | $3.19 |
| 2022 | $0.23 | −$1.36 | $0.21 | −$0.69 | — | $2.54 |
| 2023 | $0.21 | −$1.58 | $0.06 | −$1.44 | — | $1.98 |
| 2024 | $0.21 | −$1.69 | $0.05 | −$1.36 | — | $2.61 |
| 2025 | $0.17 | −$1.44 | $0.01 | −$0.85 | — | $2.14 |